⌘K
t
Tristel plc announced the appointment of Anna Wasyl as Chief Financial Officer, effective September 1, 2025. Anna Wasyl replaces Liz Dixon, who departed on June 30, 2025, after being with the Group since 2007.
| Date | 1 Sept 2025 |
| Time | 07:00:11 |
| Category | Board changes |
| ID | 2969X |
TRISTEL plc
("Tristel" or the "Company")
Confirmation of CFO Appointment
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms the appointment of Anna Wasyl as Chief Financial Officer ("CFO") of Tristel, effective from today.
As previously announced in July 2025, Anna joins the Company replacing Liz Dixon who left the business on 30 June 2025, having been with the Group since 2007. Anna brings extensive experience from her previous roles across different sectors including medical devices, robotics, and industrial automation. She has over 20 years of experience across publicly listed and venture-backed companies and joins from CMR Surgical, the Cambridge-based global surgical robotics business, where she served as Chief Commercial Partnerships and Operations Officer, having previously held the role of Group CFO.
Anna Wasyl, Chief Financial Officer of Tristel plc
Matt Sassone, CEO of Tristel plc, said: "Anna has joined at an exciting time for Tristel plc. We welcome Anna to the Tristel team and look forward to updating the market on the Company's progress at the preliminary results in October."
For further information please contact:
|
Tristel plc |
Via Walbrook PR |
||
|
Matt Sassone, Chief Executive Officer |
|||
|
Anna Wasyl, Chief Financial Officer |
|
||
|
|
|
||
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
||
|
Paul McManus / Lianne Applegarth / Anna Dunphy |
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 |
||
|
|
|
||
|
Cavendish Capital Markets Ltd |
Tel: 020 7220 0500 |
||
|
Geoff Nash / Callum Davidson/Trisyia Jamaludin (Corporate Finance) |
|
||
|
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales) |
|
||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com